Differentiation of parathyroid hormone expressing cells from human pluripotent stem cells

Krause, Diane, Yale University School of Medicine, https://orcid.org/0000-0001-9420-6947

Lawton, Betty R, Yale University

Martineau, Corine, Children's Hospital of Philadelphia

Sosa, Julie Ann, University of California, San Francisco

Roman, Sanziana, University of California, San Francisco

Gibson, Courtney E, Yale University

Levine, Michael A, Children's Hospital of Philadelphia

Krause, Diane S, Yale University

diane.krause@yale.edu

Publication date: September 4, 2020

Publisher: Dryad

https://doi.org/10.5061/dryad.djh9w0vx5

Citation

Krause, Diane et al. (2020), Differentiation of parathyroid hormone expressing cells from human pluripotent stem cells, Dryad, Dataset, https://doi.org/10.5061/dryad.djh9w0vx5

Abstract

Abstract Differentiation of pluripotent stem cells into functional parathyroid-like cells would accelerate development of important therapeutic options for subjects with parathyroid-related disorders, from the design and screening of novel pharmaceutical agents to the development of durable cellular therapies. We have established a highly reproducible directed differentiation approach leading to parathyroid hormone (PTH) expressing cells from human embryonic stem cells (hESC) and induced pluripotent stem cells (iPSC). We accomplished this through the comparison of multiple different basal media, the inclusion of the CDK inhibitor PD0332991 in both definitive endoderm (DE) and anterior foregut endoderm (AFE) stages, and a 2-stage pharyngeal endoderm (PE) series. This is the first protocol to reproducibly establish PTH expressing-cells from human pluripotent stem cells and represents a first step towards the development of functional parathyroid cells with broad applicability for medicinal and scientific investigation.

Funding

National Institutes of Health, Award: R21 CA240660